<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921659</url>
  </required_header>
  <id_info>
    <org_study_id>14-0475</org_study_id>
    <nct_id>NCT02921659</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults</brief_title>
  <official_title>Safety &amp; Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Boulder</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ChromaDex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Boulder</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of supplementation with the Nicotinamide
      Adenine Dinucleotide (NAD+) precursor compound, Nicotinamide Riboside (NR), for improving
      physiological function (vascular, motor, and cognitive) in healthy middle-aged and older
      adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall, the proposed research project has the long-term potential to influence clinical
      practice by establishing novel therapies for treating multiple domains of age-associated
      physiological dysfunction and thereby reducing the risk of clinical disease and disability.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>self reported side effects, vital signs, hematology, liver enzymes, markers of kidney function and blood chemistry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelium Dependent Dilation</measure>
    <time_frame>6 weeks</time_frame>
    <description>Brachial Artery Flow-Mediated Dilation (FMD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Stiffness</measure>
    <time_frame>6 weeks</time_frame>
    <description>Aortic Pulse Wave Velocity (PWV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Function</measure>
    <time_frame>6 weeks</time_frame>
    <description>NIH Toolbox Cognitive Function Battery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor Function</measure>
    <time_frame>6 weeks</time_frame>
    <description>NIH Toolbox Motor Function Battery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic markers of oxidative stress and inflammation</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessment of plasma C-reactive protein (CRP) and circulating and mononuclear cell-derived cytokine and antioxidant expression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, 500 mg, 2x/day for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Niagen™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Niagen™ (nicotinamide riboside chloride, ChromaDex, Inc.) 500mg, 2x/day for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Niagen™</intervention_name>
    <description>nicotinamide riboside chloride, 250mg capsules</description>
    <arm_group_label>Niagen™</arm_group_label>
    <other_name>Nicotinamide Riboside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>silicified microcrystalline cellulose, vegetarian capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide informed consent

          -  Baseline brachial flow-mediated dilation (FMD) &lt; 6%Δ (rationale: non-invasive
             screening to ensure exclusion of subjects with exceptionally high baseline endothelial
             function.

          -  Ability to perform motor and cognitive tests (e.g., can rise from a chair, walk for 2
             min, climb 10 stairs)

          -  Women will be confirmed as postmenopausal (either natural or surgical) based on
             cessation of menses for &gt;1 year.

        Exclusion Criteria:

          -  ages &lt;55 years or ≥80 years

          -  body mass index (BMI) &gt;40 kg/m2 (rationale: vascular function and blood pressure
             measurements can be inaccurate in severely obese subjects and these subjects may
             differ in many ways from normal weight, overweight or less obese subjects)

          -  not weight stable in the prior 3 months (&gt;2 kg weight change) or unwilling to remain
             weight stable throughout study (rationale: recent weight change or weight loss can
             influence vascular function)

          -  having unstable angina, acute myocardial infarction, coronary angioplasty, or
             aorto-coronary bypass surgery as defined by the occurrence of an event, symptom,
             surgery, or change in medication and/or dosage within 3 months prior to enrollment

          -  having thyroid disease that is not controlled by medications or &lt;3 month's use of a
             particular medication and/or dosage (rationale: uncontrolled thyroid diseases are
             associated with alterations in vascular function)

          -  having past or present alcohol dependence or abuse, as defined by the American
             Psychiatry Association, Diagnostic and Statistical Manual of Mental Disorders

          -  abnormal blood chemistries for renal and liver function (&gt;1 standard deviation outside
             the normal range)

          -  Moderate or severe peripheral artery disease (ankle-brachial index &lt;0.7).

          -  Insufficient health to participate in a VO2max test based on a physical examination
             and/or graded exercise test (this will be determined in accordance with stated
             contraindications for exercise testing provided by the American Heart Association).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher R Martens, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Boulder</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Translational Research Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.colorado.edu/intphys/research/cardiovascular.html</url>
    <description>Description of Research Laboratory</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2016</study_first_posted>
  <last_update_submitted>November 29, 2016</last_update_submitted>
  <last_update_submitted_qc>November 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nicotinamide riboside</keyword>
  <keyword>aging</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>endothelial dysfunction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

